Dr. Subhash C. Proothi, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 56
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 611
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
PA license MD022180E
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Lukes Hospital Bethlehem, PA
- St Luke's Hospital - Upper Bucks Campus Quakertown, PA
- St Luke's Hospital - Monroe Campus Stroudsburg, PA
- St Luke's Warren Hospital Phillipsburg, NJ
- St Luke's Miners Memorial Hospital Coaldale, PA
Medical groups
- St Lukes Physician Group Inc (2,198 clinicians)
- St Lukes Warren Physician Group PC (378 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 611
- Services billed
- 2,430
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 1,066 | 510 |
| Established patient office or other outpatient visit, 40-54 minutes | 175 | 118 |
| Established patient office or other outpatient visit, 20-29 minutes | 74 | 69 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 63 | 62 |
| New patient office or other outpatient visit, 45-59 minutes | 42 | 42 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 36 | 24 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 27 | 14 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | 14 |
| New patient office or other outpatient visit, 60-74 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Fountain Hill, PA | 139 |
| Letrozole Other prescribers in Fountain Hill, PA | 137 |
| Acyclovir Other prescribers in Fountain Hill, PA | 113 |
| Allopurinol Other prescribers in Fountain Hill, PA | 85 |
| Hydroxyurea Other prescribers in Fountain Hill, PA | 74 |
| Brukinsa (zanubrutinib) | 72 |
| Ondansetron Hcl Other prescribers in Fountain Hill, PA | 61 |
| Anastrozole Other prescribers in Fountain Hill, PA | 60 |
| Abiraterone Acetate | 58 |
| Prednisone Other prescribers in Fountain Hill, PA | 53 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 5 payments worth $437 in total to this clinician.
| Seagen Inc. | $199 |
|---|---|
| Novocure Inc. | $138 |
| AstraZeneca Pharmaceuticals LP | $99.95 |
| Education | $299 |
|---|---|
| Food and Beverage | $138 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Sep 24, 2025 | Education in-kind Company’s descriptionEducational Item | $99.95 |
| Seagen Inc. Mar 13, 2025 | Education in-kind | $99.95 |
| Seagen Inc. Jul 9, 2025 | Education in-kind | $99.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $356,076 in research payments for these studies, mostly to the institutions running them.
- Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
Beone Medicines Ltd. · Completed · NCT04116437 - A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab MK-3475 Lenvatinib E7080,MK-7902 Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastati…
Merck Sharp & Dohme LLC - An Observational Multi-center Study to Evaluate Real-World Treatment Outcomes of Durvalumab-based Regimens in Hepatobiliary Cancers
AstraZeneca UK Limited - A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia
AstraZeneca UK Limited - Phase two open label single arm trial of pirtobrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma after first line acalabrutinib progression
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.